BioWorld

Jan. 11, 2002

Corixa’s Bexxar ODAC Hearing Delayed While FDA Sorts Data

Despite reassurances from Corixa Corp. that there s nothing wrong with its lead drug candidate, Bexxar, the Seattle company s stock tumbled Thursday on news that the FDA has delayed an application hearing for the product. Read More

Access Oncology To Pay Up To $33M For Doxorubicin Analogues

Old Order Changeth; Genomics Yields Place To New Proteomics For Deciphering Gene Functions

GenVec To Collaborate With NIH On AIDS Vaccine Development

Other News To Note

Today's news in brief

BioWorld

Illustration of SCAN in Parkinson’s vs healthy subcortex

SCAN is core circuit affected in Parkinson’s disease

BioWorld Science

Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...

TL1A is overexpressed in hidradenitis suppurativa

BioWorld Science

Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...

IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa

BioWorld Science

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...

Illustration of head with maze that is missing parts

Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke

BioWorld Science

Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...